

Reassessing the link between adiposity and head and neck cancer: a Mendelian randomization study

Fernanda Morales-Berstein^{1,2}, Jasmine Khouja^{1,2}, Mark Gormley¹⁻³, Elmira Ebrahimi⁴, Shama Virani⁴, James McKay⁴, Paul Brennan⁴, Tom G Richardson^{1,2}, Caroline L Relton^{1,2,5}, George Davey Smith^{1,2}, M Carolina Borges^{1,2}, Tom Dudding¹⁻³, Rebecca C Richmond^{1,2}

¹*MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom.*

²*Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.*

³*University of Bristol Dental School, 1 Trinity Walk, Avon Street, Bristol, United Kingdom.*

⁴*Genomic Epidemiology Branch, International Agency for Research on Cancer, World Health Organization, Lyon, France.*

⁵*London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom.*

For correspondence: dy20206@bristol.ac.uk

Keywords: Head and neck cancer, adiposity, body mass index, waist-to-hip ratio, waist circumference, Mendelian randomization.

1 Abstract

2 **Background:** Adiposity has been associated with an increased risk of head and neck cancer
3 (HNC). Although body mass index (BMI) has been inversely associated with HNC risk among
4 smokers, this is likely due to confounding. Previous Mendelian randomization (MR) studies
5 could not fully discount causality between adiposity and HNC due to limited statistical power.

6 Hence, we aimed to revisit this using the largest genome-wide association study (GWAS) of
7 HNC available, which has more granular data on HNC subsites.

8

9 **Methods:** We assessed the genetically predicted effects of BMI (N=806,834), waist-to-hip
10 ratio (WHR; N=697,734) and waist circumference (N=232,101) on the risk of HNC (N=12,264
11 cases and 19,259 controls) and its subsites (oral, laryngeal, hypopharyngeal and
12 oropharyngeal cancers) using a two-sample MR framework. We used the inverse variance
13 weighted (IVW) MR approach and multiple sensitivity analyses including the weighted
14 median, weighted mode, MR-Egger, MR-PRESSO, and CAUSE approaches. We also used
15 multivariable MR (MVMR) to explore the direct effects of the adiposity measures on HNC,
16 while accounting for smoking behaviour, a well-known HNC risk factor.

17

18 **Results:** In univariable MR, higher genetically predicted BMI increased the risk of overall
19 HNC (IVW OR=1.17 per 1 standard deviation [1-SD] higher BMI, 95% CI 1.02–1.34, p=0.03),
20 with no heterogeneity across subsites (Q p=0.78). However, the effect was not consistent in
21 sensitivity analyses. The IVW effect was attenuated when smoking was included in the
22 MVMR model (OR accounting for comprehensive smoking index=0.96 per 1-SD higher BMI,
23 95% CI 0.80–1.15, p=0.64) and CAUSE indicated the IVW results could be biased by
24 correlated pleiotropy. Furthermore, we did not find a link between genetically predicted
25 WHR (IVW OR=1.05 per 1-SD higher WHR, 95% CI 0.89–1.24, p=0.53) or waist circumference
26 and HNC risk (IVW OR=0.83 per 1-SD higher waist circumference, 95% CI 0.56–1.23, p=0.35).

27

28 **Conclusions:** Our findings suggest that adiposity does not play a role in HNC risk.

29

30 Introduction

31 Head and neck cancer (HNC) is among the ten most common cancers in Europe, with an age
32 standardised incidence rate of 10.3 per 100,000 person-years[1]. Around 90% of HNCs are
33 classed as squamous cell carcinomas of the oral cavity, pharynx or larynx[2]. Tobacco
34 smoking and alcohol consumption are well-established HNC risk factors[3-9]. High-risk
35 human papillomavirus (HPV) infection has also been causally linked to the risk of HNC,
36 especially oropharyngeal cancer[10-12]. In contrast, the role of adiposity in the development
37 of HNC is less well understood.

38

39 The World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR)
40 Continuous Update Project (CUP) Expert Report published in 2018 determined higher body
41 fatness (i.e., body mass index [BMI], waist-to-hip ratio [WHR] and waist circumference) likely
42 increases the risk of HNC[13]. The CUP panel reached this conclusion even though a higher
43 BMI has been associated with a decreased risk of HNC[13], since they noted the inverse
44 association appears to be limited to current smokers. They concluded the association
45 between BMI and HNC risk may be biased among individuals who smoke (because smoking
46 is a HNC risk factor associated with lower weight). It is thought that nicotine consumption
47 could lead to appetite suppression and increased energy expenditure, which could in turn,
48 lead to weight loss (and spurious inverse associations between BMI and HNC risk[14])
49 among smokers[15]. Among never smokers, BMI has been positively associated with HNC
50 risk, in line with the evidence observed for measures of central adiposity (i.e., WHR and
51 waist circumference)[14, 16].

52

53 However, the relationship between adiposity and smoking is complex, with evidence from
54 Mendelian randomization (MR) studies suggesting higher adiposity increases the risk of
55 smoking[17, 18] while simultaneously suggesting smoking may lead to lower adiposity[17,
56 19-22]. Additionally, excess adiposity, socioeconomic deprivation and (both active and
57 passive) smoking are often strongly correlated[23-26]. Thus, the positive associations
58 between adiposity (i.e., BMI among non-smokers, WHR and waist circumference) and HNC
59 risk may not be as unbiased as they appear.

60

61 It is important to acknowledge that previous MR studies on adiposity (i.e., BMI, WHR, waist
62 circumference) and HNC risk were relatively small (maximum N=6,034 cases) and could not
63 fully discount causality due to limited statistical power[27-29]. Therefore, the aim of this MR
64 study was to revisit the link between adiposity and HNC risk using data from a HNC genome-
65 wide association study (GWAS) that includes over two times the number of cases than the
66 Genetic Associations and Mechanisms in Oncology (GAME-ON) GWAS[30] used by Gormley
67 et al.[28] (the largest to date; N=12,619, including 6,034 cases and 6,585 controls) and has
68 more granular data on HNC subsites (i.e., oral cavity, hypopharynx, oropharynx and larynx).
69 We also aimed to use multivariable MR (MVMR) to explore the direct effects of the adiposity
70 measures on HNC, while accounting for smoking behaviour.

71

72 Methods

73 Study design

74 We used a two-sample MR framework to assess the genetically predicted effects of BMI,
75 WHR and waist circumference on the risk of HNC and its subsites (oral, laryngeal,
76 hypopharyngeal and oropharyngeal cancers) among individuals of European ancestry.
77 Genetic variants associated with these adiposity traits were used as instrumental variables
78 to estimate causal effects under the three core MR assumptions[31]: 1) the genetic variants
79 are strongly associated with the adiposity trait of interest (relevance assumption); 2) the
80 distribution of the genetic variants in the population is not influenced by factors that also
81 influence HNC risk, such as population stratification, assortative mating and dynastic effects
82 (independence assumption); and 3) the genetic variants can only influence HNC risk via their
83 effect on the adiposity trait of interest (exclusion restriction assumption). This work was
84 conducted and reported according to the STROBE-MR guidelines[32] (**Additional File 1:**
85 **Appendix**).

86

87 Head and neck cancer GWAS

88 GWAS summary statistics for HNC were obtained from a European HEADSpAcE consortium
89 GWAS that excluded UK Biobank participants (N=31,523, including 12,264 cases and 19,259
90 controls) to avoid overlapping samples across the exposure and outcome datasets. It
91 includes the European GAME-ON data used by Gormley et al.[30] and has more granular
92 data on HNC subsites (i.e., oral cavity [N=21,269, including 3,091 cases and 18,178 controls],
93 hypopharynx [N=18,652, including 474 cases and 18,178 controls], HPV positive oropharynx
94 [N=20,146, including 1,980 cases and 18,166 controls], HPV negative oropharynx [N=19,114,

95 including 948 cases and 18,166 controls] and larynx [N=20,668, including 2,490 cases and
96 18,178 controls]][33].

97

98 HNC was defined based on the 10th revision of the International Classification of Diseases
99 (ICD-10)[34]. It included cancers of the oral cavity (C00.3, C00.4, C00.5, C00.6, C00.8, C00.9,
100 C02.0–C02.9 [except C02.4], C03.0–C03.9, C04.0–C04.9, C05.0–C06.9 [except C05.1, C05.2]),
101 the oropharynx (C01-C01.9, C02.4, C05.1, C05.2, and C09.0–C10.9), the hypopharynx (C12.0-
102 C13.0), the larynx (C32), and overlapping or not otherwise specified sites (C14, C05.8, C02.8,
103 C76.0)[33].

104

105 Further detail on the HEADSpAcE GWAS has been published elsewhere[33]. In brief,
106 genotype data were obtained using nine different genotyping arrays. They were
107 subsequently converted to genome build 38 for consistency across datasets. Quality control
108 (QC) procedures were conducted by genotyping array rather than by study. Samples were
109 excluded for the following reasons: sex mismatch (heterozygosity <0.8 for males and >0.2 for
110 females), autosomal heterozygosity (>3 standard deviation [SD] units from the mean),
111 missingness (>0.03), and cryptic relatedness (identity-by-descent >0.185). Single nucleotide
112 polymorphisms (SNPs) were removed due to genotype missingness (>0.01), deviations from
113 Hardy-Weinberg equilibrium ($p < 1e-05$) and low minor allele count (<20). Imputation was
114 performed using the TOPMed Imputation Server. Only SNPs with an imputation score $r^2 > 0.3$
115 and a minor allele frequency (MAF) >0.005 were included in the GWAS. The analyses were
116 conducted in PLINK using logistic regressions adjusted for sex, the top principal components
117 and imputation batch (six in total, which account for both genotyping array and study
118 differences).

119

120 Genetic instruments for adiposity

121 GWAS summary statistics for waist circumference (N=232,101) in SD units were obtained
122 from the Genetic Investigation of Anthropometric Traits (GIANT) meta-analysis by Shungin et
123 al.[35] available via the IEU OpenGWAS platform (id: ieu-a-61). GWAS summary statistics for
124 BMI (N=806,834) and WHR (N=697,734) in SD units were obtained from the latest GIANT
125 consortium's GWAS meta-analysis by Pulit et al.[36] available at
126 <https://zenodo.org/records/1251813>. The meta-analysis is the biggest to date, as it
127 combines the meta-analysis by Shungin et al.[35] with UK Biobank data. The UK Biobank
128 GWAS[36] was conducted using imputed data and the BOLT-LMM software[37]. The linear
129 mixed models (LMMs) were solely adjusted for genotyping array. GIANT and UK Biobank
130 data were meta-analysed[36] using an inverse-weighted fixed-effect meta-analysis in
131 METAL[38].

132

133 We extracted GWAS-significant SNPs for waist circumference using the standard threshold
134 ($p < 5e-08$). For BMI and WHR, we extracted them according to the stringent threshold
135 recommended by Pulit et al.[36] to account for denser imputation data ($p < 5e-09$). We then
136 performed LD-clumping to select independent lead SNPs for each exposure ($r^2 = 0.001$,
137 10,000 kb). In total, 458 and 283 and 41 SNPs remained for BMI, WHR and waist
138 circumference, respectively.

139

140 Data harmonisation

141 We extracted HNC GWAS summary statistics that corresponded to the list of SNPs selected
142 as instruments for the exposures. Proxy SNPs ($r^2 > 0.8$) were used when the instrumental

143 SNPs were not available in the outcome datasets. Proxies were identified using the
144 “extract_outcome_data” function of the “TwoSampleMR” R package and the 1000 Genomes
145 Project European reference panel. We harmonised the exposure and outcome datasets
146 using the “harmonise_data” function of the “TwoSampleMR” R package[39]. Positive strands
147 were inferred using allele frequencies and ambiguous palindromic SNPs with MAFs ≥ 0.3
148 were removed. The harmonised data used in the analyses are available in **Supplementary**
149 **Tables 1 to 6 (Additional File 2)**.

150

151 We calculated mean F-statistics and total R^2 values to assess the strength of our genetic
152 instruments after data harmonisation[40, 41].

153

154 **Statistical analysis**

155 **Main analyses**

156 The multiplicative random effects inverse-variance weighted (IVW) MR approach[42] (the
157 default IVW method of the “TwoSampleMR” package[39]) was used to investigate the
158 genetically predicted effects of BMI, WHR and waist circumference on HNC risk. We did not
159 correct our results for multiple testing, as all our exposures are strongly correlated[35, 36].

160

161 **Sensitivity analyses**

162 Because the IVW method assumes all genetic variants are valid instruments[42], which is
163 unlikely the case, three pleiotropy-robust two-sample MR methods (i.e., MR-Egger[43],
164 weighted median[44] and weighted mode[45]) were used in sensitivity analyses. We also
165 performed tests for SNP heterogeneity (i.e., Q statistic test)[46] and directional horizontal
166 pleiotropy (i.e., MR-Egger intercept test)[43]. When directional horizontal pleiotropy was

167 identified, we used the intercept value to evaluate the extent of the bias. The MR-
168 PRESSO[47] method was used to identify outliers (outlier test $p < 0.05$) and calculate outlier-
169 corrected causal estimates when there was evidence of SNP heterogeneity. The MR-PRESSO
170 distortion test was used to evaluate differences between the outlier-corrected and IVW
171 estimates.

172

173 In addition, we ran MVMR[48] analyses to evaluate the direct effects of adiposity measures
174 with evidence of a total effect in our main analyses. The aim of the MVMR analyses was to
175 separate the effect of adiposity from smoking behaviour (a well-known HNC risk factor
176 which has a complex relationship with adiposity) in the development of HNC. We obtained
177 genetic instruments for smoking behaviour from two different sources: a smoking initiation
178 GWAS (N=805,431 excluding 23andme) derived by the GWAS and Sequencing Consortium of
179 Alcohol and Nicotine use (GSCAN)[49] and a comprehensive smoking index (CSI; a measure
180 of lifetime smoking that captures smoking heaviness, duration and cessation) GWAS
181 (N=462,690) conducted by Wootton et al.[50]. Each was separately investigated in a MVMR
182 framework. For each smoking trait, we selected SNPs that passed the GWAS-significance and
183 independence thresholds ($p < 5e-08$, $r^2 = 0.001$, 10,000 kb) and combined them with the list of
184 SNPs identified as instruments for the relevant exposure. We then performed LD-clumping
185 across the combined list of SNPs, to then use these independent SNPs in MVMR analyses.
186 The exposure and outcome datasets were harmonised to the same effect allele using the
187 “harmonise_data” function of the “TwoSampleMR” R package[39]. We formatted the data
188 using the “format_mvmmr” function of the “MVMR” R package, calculated the conditional F-
189 statistics for the MVMR instruments using the “strength_mvmmr” function and ran the MVMR
190 analyses using the “ivw_mvmmr” function.

191

192 Since we used large GWAS datasets for the selection of our genetic instruments, our
193 analyses are at an increased likelihood of being biased due to correlated horizontal
194 pleiotropy (sometimes referred to as heritable confounding), which occurs when the genetic
195 instruments are associated with the exposure through their effect on confounders of an
196 exposure-outcome association[51, 52]. To mitigate this bias, we used Steiger filtering[53] to
197 remove SNPs that are more strongly associated with smoking behaviour (a confounder of
198 the exposure-outcome association) than the exposure of interest, as proposed by Sanderson
199 et al.[54]. We also used Causal Analysis using Summary Effect Estimates (CAUSE)[52],
200 another pleiotropy-robust MR method, to further investigate whether our results could be
201 biased by correlated horizontal pleiotropy. CAUSE uses Bayesian expected log pointwise
202 posterior predictive densities (ELPDs) to compare null, sharing and causal models. A higher
203 ELPD represents a better model fit, so a positive delta ELPD (where delta ELPD = ELPD model
204 1 - ELPD model 2) suggests model 1 fits the data better than model 2, while a negative delta
205 ELPD suggests the opposite. If we find evidence to reject the null hypothesis that the sharing
206 model (i.e. causal effect fixed at zero) fits the data at least as well as the causal model (i.e.
207 causal effect can differ from zero), our findings would be consistent with a causal effect.
208 Steiger filtering and CAUSE analyses were only conducted for adiposity measures with
209 evidence of a total effect in our main IVW analyses.

210

211 Moreover, we used the MR-Clust algorithm[55] to find distinct SNP clusters underlying the
212 relationship between adiposity measures with evidence of a total effect in our main analyses
213 and HNC. The identification of substantial clusters could provide insight into potential causal
214 mechanisms. It could also flag pleiotropic variables that are associated with SNPs in each

215 cluster. We filtered SNPs with conditional probabilities <0.8. At least four SNPs needed to
 216 remain per cluster for a substantial cluster to be reported.

217

218 Secondary analyses

219 In secondary analyses, we investigated the role of BMI, WHR and waist circumference on the
 220 risk of HNC by subsite (i.e., oral cavity, hypopharynx, HPV positive oropharynx, HPV negative
 221 oropharynx and larynx). We used a Cochran's Q test to examine heterogeneity across HNC
 222 subsites.

223

224 We also explored the role of other adiposity-related anthropometric measures on the risk of
 225 HNC and its subsites. These anthropometric measures included: 1) four body shape principal
 226 components[56], 2) childhood and adulthood body size[57], 3) metabolically favourable and
 227 unfavourable adiposity[58], 4) body fat percentage, and 5) brain and adipose tissue-specific
 228 BMI[59]. The data sources for these traits are summarised in **Table 1**.

229

230 *Table 1. Data sources and instruments for other adiposity-related anthropometric measures.*

Study	Year	Data source	Trait	Unit	Download link or OpenGWAS ID
Ried et al. [56]	2016	GIANT	Body shape PC1 (overall adiposity)	SD	https://www.joelhirsc-hhornlab.org/giant-consortium-results
			Body shape PC2 (tall and slim vs short and plump)	SD	
			Body shape PC3 (tall with small hip vs short with big hip)	SD	
			Body shape PC4 (high BMI and weight with small hip and waist vs low BMI and weight with big hip and waist)	SD	
Richardson et al. [57]	2020	UKB	Childhood body size	Change in body size category	"ieu-b-5107"
			Adulthood body size	Change in body size category	"ieu-b-5118"
Martin et al. [58]	2021	UKB	Metabolically favourable adiposity	SD	https://doi.org/10.2337/figshare.14555463

			Metabolically unfavourable adiposity	SD	.v1
MRC-IEU (Elsworth)	2018	UKB	Body fat percentage	SD	"ukb-b-8909"
Leyden et al. [59]	2022	GIANT + UKB	Brain tissue-specific BMI	SD	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874216/bin/mc2.xlsx
			Adipose tissue-specific BMI	SD	

231 Abbreviations: BMI, body mass index; GIANT, Genetic Investigation of Anthropometric Traits; N, number; PC, principal
232 component; SD, standard deviation; SNP, single-nucleotide polymorphism; UKB, UK Biobank.
233
234

235 Statistical software

236 We completed all MR analyses using R software version 4.4.0 and the "TwoSampleMR"

237 v0.6.3, "MRPRESSO" v1.0, "MVMR" v0.4, "cause" v1.2.0 and "mrclust" v0.1.0 R packages.

238 The "ggplot2" v3.5.1 and "ggforestplot" v0.1.0 R packages were used to create forest plots.

239 The code used to run the MR analyses is available at

240 http://github.com/fernandam93/adiposity_HNC_MR.

241

242 Results

243 Genetic instruments for BMI, WHR and waist circumference

244 After data harmonisation and the removal of ambiguous palindromic SNPs, 442 genetic

245 variants remained as instruments for BMI, while 267 remained for WHR and 37 for waist

246 circumference (**Additional File 2: Supplementary Table 1**). The mean F-statistic for BMI was

247 77 (range 33–844) and the total variance explained was 4.8%. For WHR, the mean F-statistic

248 was 73 (range 33–820) and the total variance explained was 3.1%. For waist circumference,

249 the mean F-statistic was 50 (range 29–144) and the total variance explained was 0.8%.

250

251 The F-statistics and R^2 values for the other adiposity-related anthropometric measures have

252 been summarised in **Table 2**.

253

254 *Table 2. F-statistics and variance explained for other adiposity-related anthropometric*
255 *measures.*

Trait	N SNPs before/after harmonisation	Total R ²	Mean F-statistics (range)
Body shape PC1 (overall adiposity)	29/28	16%	54 (28–302)
Body shape PC2 (tall and slim vs short and plump)	84/81	3.4%	54 (30–211)
Body shape PC3 (tall with small hip vs short with big hip)	28/27	0.9%	41 (30–82)
Body shape PC4 (high BMI and weight with small hip and waist vs low BMI and weight with big hip and waist)	10/ 10	24.7%	42 (30–98)
Childhood body size	206/198	3.4%	78 (28–1102)
Adulthood body size	339/324	4.2%	59 (30–1109)
Metabolically favourable adiposity	34/31	0.4%	64 (25–400)
Metabolically unfavourable adiposity	29/27	0.8%	131 (25–400)
Body fat percentage	377/360	4.7%	59 (30–682)
Brain tissue-specific BMI	140/133	1.2%	61 (29–270)
Adipose tissue-specific BMI	86 /81	0.7%	63 (30–270)

256 Abbreviations: BMI, body mass index; N, number; PC, principal component; SNP, single-nucleotide polymorphism.

257

258

259 **Genetically predicted effects of BMI, WHR and waist circumference on HNC** 260 **risk**

261 In univariable MR, higher genetically predicted BMI increased the risk of overall HNC (IVW

262 OR=1.17 per 1 standard deviation [1-SD] higher BMI, 95% CI 1.02–1.34, p=0.03), with no

263 heterogeneity across subsites (Q p=0.78) (**Figure 1, Supplementary Figure 1 and Additional**

264 **File 2: Supplementary Table 7**). However, the positive relationship between genetically

265 predicted BMI and HNC risk was not consistent across the MR-Egger, weighted median and

266 weighted mode analyses, with point estimates in opposing directions and confidence

267 intervals including the null. The Q statistic and MR-Egger intercept tests suggested that there

268 was heterogeneity across individual SNP estimates (Q=609, p<0.001) and a minor degree of

269 unbalanced horizontal pleiotropy (intercept=0.007, p=0.03) that could have biased the main

270 IVW results (**Additional File 2: Supplementary Tables 8 and 9**). Although the MR-PRESSO

271 analysis identified two outliers (i.e., rs11611246 and rs9603697), the distortion test

272 suggested the outlier-corrected estimate (outlier-corrected IVW OR=1.14 per 1-SD higher
273 BMI, 95% CI 1.00–1.30, $p=0.05$) was not statistically different to the main IVW estimate
274 ($p=0.94$) (**Additional File 2: Supplementary Table 10**).

275

276 Furthermore, we did not find a link between genetically predicted WHR and HNC risk (IVW
277 OR=1.05 per 1-SD higher WHR, 95% CI 0.89–1.24, $p=0.53$) and there was no heterogeneity
278 across subsites ($Q\ p=0.15$) (**Figure 2, Supplementary Figure 2 and Additional File 2:**
279 **Supplementary Table 7**). MR-Egger, weighted median and weighted mode results were
280 consistent with a null effect. The Q statistic and MR-Egger intercept tests suggested that
281 there was some evidence of SNP heterogeneity ($Q=332$, $p=0.004$) and unbalanced horizontal
282 pleiotropy (intercept=0.008, $p=0.03$) (**Additional File 2: Supplementary Tables 8 and 9**). The
283 MR-PRESSO analysis did not identify any significant outliers (**Additional File 2:**
284 **Supplementary Table 10**).

285

286 Similarly, we did not find a genetically predicted effect of waist circumference on HNC risk
287 (IVW OR=0.83 per 1-SD higher waist circumference, 95% CI 0.56–1.23, $p=0.35$) or evidence
288 of heterogeneity across subsites ($Q\ p=0.60$) (**Figure 3, Supplementary Figure 3 and**
289 **Additional File 2: Supplementary Table 7**). The MR-Egger, weighted median and weighted
290 mode consistently suggested the absence of an effect of waist circumference on HNC risk.
291 The Q statistic and MR-Egger intercept tests suggested SNP heterogeneity ($Q=89$, $p<0.001$)
292 but no unbalanced horizontal pleiotropy (intercept=-0.019, $p=0.30$) (**Additional File 2:**
293 **Supplementary Tables 8 and 9**). The MR-PRESSO analysis identified three outliers (i.e.,
294 rs3127553, rs6440003 and rs806794) but the distortion test suggested the outlier-corrected
295 estimate (outlier-corrected IVW OR=0.77 per 1-SD higher waist circumference, 95% CI 0.59–

296 1.01, $p=0.07$) was not statistically different to the main IVW estimate ($p=0.73$) (**Additional**
297 **File 2: Supplementary Table 10**).

298

299 **MVMR estimates for BMI on HNC risk after accounting for smoking behaviour**

300 The effect of BMI on HNC risk was attenuated when smoking behaviour was included in the
301 MVMR model (OR accounting for CSI=0.93 per 1-SD higher BMI, 95% CI 0.78–1.12, $p=0.47$;
302 OR accounting for smoking initiation=1.09 per 1-SD higher BMI, 95% CI 0.88–1.34, $p=0.43$)
303 (**Figures 4 and 5 and Additional File 2: Supplementary Table 11**). Genetically predicted
304 smoking behaviour increased the risk of HNC even after accounting for BMI (CSI OR
305 accounting for BMI=4.25 per 1-SD higher CSI, 95% CI 3.18–5.67, $p<0.001$; SI OR accounting
306 for BMI=2.10 per 1-SD higher SI, 95% CI 1.61–2.73, $p<0.001$). The conditional F-statistics for
307 the BMI estimates were 30.5 and 30.3 in the CSI and smoking initiation analyses,
308 respectively (**Additional File 2: Supplementary Table 11**). They were slightly lower for the
309 smoking behaviour estimates conditioning on BMI (13.4 and 19.5 in the CSI and smoking
310 initiation analyses, respectively).

311

312 **MR estimate for BMI on HNC risk after Steiger filtering SNPs more strongly** 313 **associated with smoking behaviour than BMI**

314 After removing six SNPs (i.e., rs10002111, rs2503185, rs264941, rs10858334, rs225882,
315 rs2273175) that were more strongly associated with smoking behaviour (i.e., CSI or smoking
316 initiation) than BMI, the genetically predicted effect of BMI on HNC risk slightly attenuated
317 towards the null (Steiger filtered IVW OR=1.14 per 1-SD higher BMI, 95% CI 1.00–1.31,
318 $p=0.05$) (**Additional File 2: Supplementary Table 12**).

319

320 CAUSE estimate for BMI on HNC risk

321 We did not find evidence against bias due to correlated pleiotropy, since the causal model
322 did not fit the data much better than the sharing model (CAUSE OR 1.12 per 1-SD higher BMI,
323 95% credible interval 0.93–1.34, delta ELPD for sharing vs causal=-0.07, $p=0.47$)
324 (**Supplementary Figure 4**). Interestingly, neither the sharing nor the causal model fitted the
325 data much better than the null model (delta ELPD for null vs sharing=-0.39, $p=0.36$; and
326 delta ELPD for null vs causal=-0.46, $p=0.41$).

327

328 MR-Clust estimates for the relationship between BMI and HNC risk

329 After filtering SNPs with conditional probabilities <0.8 and clusters with fewer than four
330 SNPs (e.g., cluster 1, as only three of 17 SNPs remained after probability filtering), only a null
331 cluster including 372 SNPs (424 before filtering) remained in the MR-Clust output for BMI
332 and HNC risk (**Supplementary Figure 5 and Additional File 2: Supplementary Table 13**).
333 Hence, the MR-Clust analysis did not reveal any mechanistic pathways underlying the effect
334 observed.

335

336 Genetically predicted effects of other adiposity-related anthropometric

337 measures on HNC risk

338 We did not find consistent evidence of genetically predicted effects of other anthropometric
339 measures on HNC risk (**Supplementary Figures 6–10 and Additional File 2: Supplementary**
340 **Table 14**). The IVW estimate for PC2 capturing a combination of taller height and slimmer
341 waist suggested this body shape decreased HNC risk (OR=0.86, 95% CI 0.75–0.99, $p=0.04$)
342 (**Supplementary Figure 6b**). Similarly, the IVW estimate for PC3 capturing a combination of
343 taller height and narrower hips suggested this body shape also reduced HNC risk (OR=0.73,

344 95% CI 0.55–0.97, $p=0.03$) (**Supplementary Figure 6c**). However, these inverse relationships
345 were not consistent with results obtained using pleiotropy-robust methods (i.e., MR-Egger,
346 weighted median and weighted mode).

347

348 Discussion

349 In this MR study, we reaffirmed that there is no clear evidence of a genetically predicted
350 effect of adiposity (i.e., BMI, WHR and waist circumference) or related anthropometric
351 measures on the risk of HNC or its subsites. Although we found higher genetically predicted
352 BMI increased the risk of overall HNC in the main univariable MR analysis, this was not
353 consistent across the sensitivity analyses. Notably, the MVMR results suggested the main
354 analysis may have been biased by smoking (and/or related traits), as the effect disappeared
355 after accounting for smoking behaviour. The results obtained after Steiger filtering SNPs
356 more strongly associated with smoking behaviour than BMI suggested correlated pleiotropy
357 may have been partly biasing the BMI-HNC estimate. CAUSE, which is more robust to
358 correlated pleiotropy than the IVW method, further supported this hypothesis.

359

360 Our results are consistent with previous MR studies that suggest adiposity does not
361 influence HNC risk[27-29]. Gormley et al.[28] did not find a genetically predicted effect of
362 adiposity on combined oral and oropharyngeal cancer when investigating either BMI
363 (OR=0.89 per 1-SD, 95% CI 0.72–1.09, $p=0.26$), WHR (OR=0.98 per 1-SD, 95% CI 0.74–1.29,
364 $p=0.88$) or waist circumference (OR=0.73 per 1-SD, 95% CI 0.52–1.02, $p=0.07$) as risk factors.
365 Similarly, a large two-sample MR study by Vithayathil et al.[29] including 367,561 UK
366 Biobank participants (of which 1,983 were HNC cases) found no link between BMI and HNC

367 risk (OR=0.98 per 1-SD higher BMI, 95% CI 0.93–1.02, $p=0.35$). Larsson et al.[27] meta-
368 analysed Vithayathil et al.'s[29] findings with results obtained using FinnGen data to increase
369 the sample size even further (N=586,353, including 2,109 cases), but still did not find a
370 genetically predicted effect of BMI on HNC risk (OR=0.96 per 1-SD higher BMI, 95% CI 0.77–
371 1.19, $p=0.69$).

372

373 In our study, we found some evidence that the genetically predicted effect of BMI on HNC
374 risk was influenced by smoking. This could be due to the bidirectional relationship between
375 smoking and adiposity reported in previous MR studies[17-22] or due to their shared genetic
376 architecture[60, 61]. A strength of our study was that it was the first to exploit MVMR to
377 disentangle the effects of BMI and smoking behaviour on the risk of HNC and its subsites. An
378 advantage of our approach compared to conducting univariable MR analyses stratified by
379 smoking status is that the former does not induce collider bias and provides estimates of
380 direct effects irrespective of horizontal pleiotropy or mediation. Yet, we acknowledge the
381 smoking behaviour traits used in our MVMR analyses likely capture more than just smoking,
382 since some of the SNPs used to instrument these traits have been associated with risk-taking
383 phenotypes and socioeconomic factors[62-65]. This places limits in the inferences that can
384 be made about smoking in the context of mediation.

385

386 An important strength of our study was that the HEADSpAcE consortium GWAS used had a
387 large sample size which conferred more statistical power to detect effects of adiposity on
388 HNC risk compared to previous MR analyses[27-29], increasing one's confidence in the null
389 nature of the estimates. Furthermore, the availability of data on more HNC subsites,
390 including oropharyngeal cancers by HPV status, allowed us to investigate the relationship

391 between adiposity and HNC risk in more detail than previous MR studies which limited their
392 subsite analyses to oral cavity and overall oropharyngeal cancers[28, 66]. This is relevant
393 because distinct HNC subsites are known to have different aetiologies[67], although we did
394 not find evidence of heterogeneity across subsites in our study.

395

396 We acknowledge that a major limitation of MR studies, including ours, is that several
397 untestable assumptions are required to make accurate causal inferences. It is unlikely that
398 our findings were influenced by weak instrument bias (i.e., violating the relevance
399 assumption) because we used strong genetic instruments to proxy our adiposity traits.
400 However, the independence assumption of no genetic confounding and the exclusion
401 restriction assumption of no horizontal pleiotropy could have been violated.

402

403 While our study contributes valuable evidence on the role of adiposity in the development
404 of HNC, we recognise there is a need for additional research on the subject. Our study was
405 limited to individuals of European ancestry, so our findings should be replicated in other
406 ancestry groups before being generalised to non-European populations. Moreover, further
407 research is needed to understand the biology underlying the complex relationship between
408 smoking and adiposity, especially since it may be difficult to intervene on one without
409 influencing the other[17].

410

411 Conclusions

412 In conclusion, this study indicates that adiposity does not play a role in HNC risk. Although
413 we did not find strong evidence of a causal effect of adiposity on HNC, obesity is an

414 established risk factor for multiple cancers and other chronic diseases[27, 68, 69]. Hence

415 there is still value in aiming to reduce the levels of excess adiposity in the population.

416

417 References

- 418 1. **Global Cancer Observatory: Cancer Today (version 1.1)**
419 [<https://gco.iarc.who.int/today>]
- 420 2. Curado MP, Hashibe M: **Recent changes in the epidemiology of head and neck**
421 **cancer.** *Curr Opin Oncol* 2009, **21**(3):194-200.
- 422 3. Hashibe M, Brennan P, Benhamou S, Castellsague X, Chen C, Curado MP, Dal Maso L,
423 Daudt AW, Fabianova E, Fernandez L *et al*: **Alcohol drinking in never users of tobacco,**
424 **cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled**
425 **analysis in the International Head and Neck Cancer Epidemiology Consortium.** *J*
426 *Natl Cancer Inst* 2007, **99**(10):777-789.
- 427 4. Lee YC, Boffetta P, Sturgis EM, Wei Q, Zhang ZF, Muscat J, Lazarus P, Matos E, Hayes
428 RB, Winn DM *et al*: **Involuntary smoking and head and neck cancer risk: pooled**
429 **analysis in the International Head and Neck Cancer Epidemiology Consortium.**
430 *Cancer Epidemiol Biomarkers Prev* 2008, **17**(8):1974-1981.
- 431 5. Purdue MP, Hashibe M, Berthiller J, La Vecchia C, Dal Maso L, Herrero R, Franceschi S,
432 Castellsague X, Wei Q, Sturgis EM *et al*: **Type of alcoholic beverage and risk of head**
433 **and neck cancer--a pooled analysis within the INHANCE Consortium.** *Am J*
434 *Epidemiol* 2009, **169**(2):132-142.
- 435 6. Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, Curado MP, Dal
436 Maso L, Daudt AW, Fabianova E *et al*: **Interaction between tobacco and alcohol use**
437 **and the risk of head and neck cancer: pooled analysis in the International Head and**
438 **Neck Cancer Epidemiology Consortium.** *Cancer Epidemiol Biomarkers Prev* 2009,
439 **18**(2):541-550.
- 440 7. Marron M, Boffetta P, Zhang ZF, Zaridze D, Wunsch-Filho V, Winn DM, Wei Q,
441 Talamini R, Szeszenia-Dabrowska N, Sturgis EM *et al*: **Cessation of alcohol drinking,**
442 **tobacco smoking and the reversal of head and neck cancer risk.** *Int J Epidemiol* 2010,
443 **39**(1):182-196.
- 444 8. Humans IWGoTEoCRt: **Tobacco smoke and involuntary smoking.** *IARC Monogr Eval*
445 *Carcinog Risks Hum* 2004, **83**:1-1438.
- 446 9. Gormley M, Dudding T, Sanderson E, Martin RM, Thomas S, Tyrrell J, Ness AR,
447 Brennan P, Munafo M, Pring M *et al*: **A multivariable Mendelian randomization**
448 **analysis investigating smoking and alcohol consumption in oral and oropharyngeal**
449 **cancer.** *Nat Commun* 2020, **11**(1):6071.
- 450 10. Sabatini ME, Chiozza S: **Human papillomavirus as a driver of head and neck cancers.**
451 *Br J Cancer* 2020, **122**(3):306-314.
- 452 11. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML,
453 Daniel RW, Viglione M, Symer DE *et al*: **Evidence for a causal association between**
454 **human papillomavirus and a subset of head and neck cancers.** *J Natl Cancer Inst*
455 2000, **92**(9):709-720.

- 456 12. de Martel C, Georges D, Bray F, Ferlay J, Clifford GM: **Global burden of cancer**
457 **attributable to infections in 2018: a worldwide incidence analysis.** *Lancet Glob*
458 *Health* 2020, **8**(2):e180-e190.
- 459 13. Research WCRFAIfC: **Diet, nutrition, physical activity and cancers of the mouth,**
460 **pharynx and larynx.** In: *Continuous Update Project Expert Report.* 2018.
- 461 14. Gaudet MM, Kitahara CM, Newton CC, Bernstein L, Reynolds P, Weiderpass E,
462 Kreimer AR, Yang G, Adami HO, Alavanja MC *et al*: **Anthropometry and head and**
463 **neck cancer:a pooled analysis of cohort data.** *Int J Epidemiol* 2015, **44**(2):673-681.
- 464 15. Jo YH, Talmage DA, Role LW: **Nicotinic receptor-mediated effects on appetite and**
465 **food intake.** *J Neurobiol* 2002, **53**(4):618-632.
- 466 16. Watts EL, Moore SC, Gunter MJ, Chatterjee N: **Adiposity and cancer: meta-analysis,**
467 **mechanisms, and future perspectives.** *medRxiv*
468 2024:<https://doi.org/10.1101/2024.1102.1116.24302944>.
- 469 17. Taylor AE, Richmond RC, Palviainen T, Loukola A, Wootton RE, Kaprio J, Relton CL,
470 Davey Smith G, Munafò MR: **The effect of body mass index on smoking behaviour**
471 **and nicotine metabolism: a Mendelian randomization study.** *Hum Mol Genet* 2019,
472 **28**(8):1322-1330.
- 473 18. Carreras-Torres R, Johansson M, Haycock PC, Relton CL, Davey Smith G, Brennan P,
474 Martin RM: **Role of obesity in smoking behaviour: Mendelian randomisation study**
475 **in UK Biobank.** *BMJ* 2018, **361**:k1767.
- 476 19. Asvold BO, Bjorngaard JH, Carslake D, Gabrielsen ME, Skorpen F, Smith GD,
477 Romundstad PR: **Causal associations of tobacco smoking with cardiovascular risk**
478 **factors: a Mendelian randomization analysis of the HUNT Study in Norway.** *Int J*
479 *Epidemiol* 2014, **43**(5):1458-1470.
- 480 20. Freathy RM, Kazeem GR, Morris RW, Johnson PC, Paternoster L, Ebrahim S, Hattersley
481 AT, Hill A, Hingorani AD, Holst C *et al*: **Genetic variation at CHRNA5-CHRNA3-CHRNA4**
482 **interacts with smoking status to influence body mass index.** *Int J Epidemiol* 2011,
483 **40**(6):1617-1628.
- 484 21. Taylor AE, Morris RW, Fluharty ME, Bjorngaard JH, Asvold BO, Gabrielsen ME,
485 Campbell A, Marioni R, Kumari M, Hallfors J *et al*: **Stratification by smoking status**
486 **reveals an association of CHRNA5-A3-B4 genotype with body mass index in never**
487 **smokers.** *PLoS Genet* 2014, **10**(12):e1004799.
- 488 22. Morris RW, Taylor AE, Fluharty ME, Bjorngaard JH, Asvold BO, Elvestad Gabrielsen M,
489 Campbell A, Marioni R, Kumari M, Korhonen T *et al*: **Heavier smoking may lead to a**
490 **relative increase in waist circumference: evidence for a causal relationship from a**
491 **Mendelian randomisation meta-analysis. The CARTA consortium.** *BMJ Open* 2015,
492 **5**(8):e008808.
- 493 23. Yang S, Lynch J, Schulenberg J, Diez Roux AV, Raghunathan T: **Emergence of**
494 **socioeconomic inequalities in smoking and overweight and obesity in early**
495 **adulthood: the national longitudinal study of adolescent health.** *Am J Public Health*
496 2008, **98**(3):468-477.
- 497 24. Marmot M, Bell R: **Social determinants and non-communicable diseases: time for**
498 **integrated action.** *BMJ* 2019, **364**:l251.
- 499 25. Marmot M: **The health gap: Doctors and the social determinants of health.** *Scand J*
500 *Public Health* 2017, **45**(7):686-693.
- 501 26. Filippidis FT, Agaku IT, Girvalaki C, Jimenez-Ruiz C, Ward B, Gratziou C, Vardavas CI,
502 Tobacco Control Committee of the European Respiratory S: **Relationship of**

- 503 **secondhand smoke exposure with sociodemographic factors and smoke-free**
504 **legislation in the European Union.** *Eur J Public Health* 2016, **26**(2):344-349.
- 505 27. Larsson SC, Burgess S: **Causal role of high body mass index in multiple chronic**
506 **diseases: a systematic review and meta-analysis of Mendelian randomization**
507 **studies.** *BMC Med* 2021, **19**(1):320.
- 508 28. Gormley M, Dudding T, Thomas SJ, Tyrrell J, Ness AR, Pring M, Legge D, Davey Smith
509 G, Richmond RC, Vincent EE *et al*: **Evaluating the effect of metabolic traits on oral**
510 **and oropharyngeal cancer risk using Mendelian randomization.** *Elife* 2023, **12**.
- 511 29. Vithayathil M, Carter P, Kar S, Mason AM, Burgess S, Larsson SC: **Body size and**
512 **composition and risk of site-specific cancers in the UK Biobank and large**
513 **international consortia: A mendelian randomisation study.** *PLoS Med* 2021,
514 **18**(7):e1003706.
- 515 30. Lesueur C, Diergaarde B, Olshan AF, Wunsch-Filho V, Ness AR, Liu G, Lacko M, Eluf-
516 Neto J, Franceschi S, Lagiou P *et al*: **Genome-wide association analyses identify new**
517 **susceptibility loci for oral cavity and pharyngeal cancer.** *Nat Genet* 2016,
518 **48**(12):1544-1550.
- 519 31. Davies NM, Holmes MV, Davey Smith G: **Reading Mendelian randomisation studies:**
520 **a guide, glossary, and checklist for clinicians.** *BMJ* 2018, **362**:k601.
- 521 32. Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA,
522 VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N *et al*: **Strengthening the**
523 **Reporting of Observational Studies in Epidemiology Using Mendelian**
524 **Randomization: The STROBE-MR Statement.** *JAMA* 2021, **326**(16):1614-1621.
- 525 33. Ebrahimi E, Sangphukieo A, Park H, Gaborieau V, Ferreiro-Iglesias A, Diergaarde B,
526 Ahrens W, Alemany L, Arantes L, Betka J *et al*: **Cross-ancestral GWAS identifies 29**
527 **novel variants across Head and Neck Cancer subsites.** *medRxiv*
528 2024:<https://doi.org/10.1101/2024.1111.1118.24317473>.
- 529 34. World Health O, World Health O: **ICD-10 : international statistical classification of**
530 **diseases and related health problems**, Tenth revision, Fifth edition. edn. Geneva:
531 World Health Organization; 2016.
- 532 35. Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Magi R, Strawbridge
533 RJ, Pers TH, Fischer K, Justice AE *et al*: **New genetic loci link adipose and insulin**
534 **biology to body fat distribution.** *Nature* 2015, **518**(7538):187-196.
- 535 36. Pulit SL, Stoneman C, Morris AP, Wood AR, Glastonbury CA, Tyrrell J, Yengo L, Ferreira
536 T, Marouli E, Ji Y *et al*: **Meta-analysis of genome-wide association studies for body**
537 **fat distribution in 694 649 individuals of European ancestry.** *Hum Mol Genet* 2019,
538 **28**(1):166-174.
- 539 37. Loh PR, Tucker G, Bulik-Sullivan BK, Vilhjalmsdottir BJ, Finucane HK, Salem RM,
540 Chasman DI, Ridker PM, Neale BM, Berger B *et al*: **Efficient Bayesian mixed-model**
541 **analysis increases association power in large cohorts.** *Nat Genet* 2015, **47**(3):284-
542 290.
- 543 38. Willer CJ, Li Y, Abecasis GR: **METAL: fast and efficient meta-analysis of genomewide**
544 **association scans.** *Bioinformatics* 2010, **26**(17):2190-2191.
- 545 39. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S,
546 Bowden J, Langdon R *et al*: **The MR-Base platform supports systematic causal**
547 **inference across the human phenome.** *Elife* 2018, **7**.

- 548 40. Palmer TM, Lawlor DA, Harbord RM, Sheehan NA, Tobias JH, Timpson NJ, Davey
549 Smith G, Sterne JA: **Using multiple genetic variants as instrumental variables for**
550 **modifiable risk factors**. *Stat Methods Med Res* 2012, **21**(3):223-242.
- 551 41. Burgess S, Thompson SG: **Bias in causal estimates from Mendelian randomization**
552 **studies with weak instruments**. *Stat Med* 2011, **30**(11):1312-1323.
- 553 42. Burgess S, Butterworth A, Thompson SG: **Mendelian randomization analysis with**
554 **multiple genetic variants using summarized data**. *Genet Epidemiol* 2013, **37**(7):658-
555 665.
- 556 43. Bowden J, Davey Smith G, Burgess S: **Mendelian randomization with invalid**
557 **instruments: effect estimation and bias detection through Egger regression**. *Int J*
558 *Epidemiol* 2015, **44**(2):512-525.
- 559 44. Bowden J, Davey Smith G, Haycock PC, Burgess S: **Consistent Estimation in**
560 **Mendelian Randomization with Some Invalid Instruments Using a Weighted**
561 **Median Estimator**. *Genet Epidemiol* 2016, **40**(4):304-314.
- 562 45. Hartwig FP, Davey Smith G, Bowden J: **Robust inference in summary data Mendelian**
563 **randomization via the zero modal pleiotropy assumption**. *Int J Epidemiol* 2017,
564 **46**(6):1985-1998.
- 565 46. Bowden J, Del Greco MF, Minelli C, Zhao Q, Lawlor DA, Sheehan NA, Thompson J,
566 Davey Smith G: **Improving the accuracy of two-sample summary-data Mendelian**
567 **randomization: moving beyond the NOME assumption**. *Int J Epidemiol* 2019,
568 **48**(3):728-742.
- 569 47. Verbanck M, Chen CY, Neale B, Do R: **Detection of widespread horizontal pleiotropy**
570 **in causal relationships inferred from Mendelian randomization between complex**
571 **traits and diseases**. *Nat Genet* 2018, **50**(5):693-698.
- 572 48. Sanderson E, Davey Smith G, Windmeijer F, Bowden J: **An examination of**
573 **multivariable Mendelian randomization in the single-sample and two-sample**
574 **summary data settings**. *Int J Epidemiol* 2019, **48**(3):713-727.
- 575 49. Saunders GRB, Wang X, Chen F, Jang S-K, Liu M, Wang C, Gao S, Jiang Y,
576 Khunsriraksakul C, Otto JM *et al*: **Genetic diversity fuels gene discovery for tobacco**
577 **and alcohol use**. *Nature* 2022, **612**(7941):720-724.
- 578 50. Wootton RE, Richmond RC, Stuijzand BG, Lawn RB, Sallis HM, Taylor GMJ, Hemani G,
579 Jones HJ, Zammit S, Davey Smith G *et al*: **Evidence for causal effects of lifetime**
580 **smoking on risk for depression and schizophrenia: a Mendelian randomisation**
581 **study**. *Psychol Med* 2020, **50**(14):2435-2443.
- 582 51. Darrous L, Mounier N, Kutalik Z: **Simultaneous estimation of bi-directional causal**
583 **effects and heritable confounding from GWAS summary statistics**. *Nat Commun*
584 2021, **12**(1):7274.
- 585 52. Morrison J, Knoblauch N, Marcus JH, Stephens M, He X: **Mendelian randomization**
586 **accounting for correlated and uncorrelated pleiotropic effects using genome-wide**
587 **summary statistics**. *Nat Genet* 2020, **52**(7):740-747.
- 588 53. Hemani G, Tilling K, Davey Smith G: **Orienting the causal relationship between**
589 **imprecisely measured traits using GWAS summary data**. *PLoS Genet* 2017,
590 **13**(11):e1007081.
- 591 54. Sanderson E, Rosoff D, Palmer T, Tilling K, Smith GD, Hemani G: **Bias from heritable**
592 **confounding in Mendelian randomization studies**. *medRxiv*
593 2024:2024.2009.2005.24312293.

- 594 55. Foley CN, Mason AM, Kirk PDW, Burgess S: **MR-Clust: clustering of genetic variants**
595 **in Mendelian randomization with similar causal estimates.** *Bioinformatics* 2021,
596 **37(4):531-541.**
- 597 56. Ried JS, Jeff MJ, Chu AY, Bragg-Gresham JL, van Dongen J, Huffman JE, Ahluwalia TS,
598 Cadby G, Eklund N, Eriksson J *et al*: **A principal component meta-analysis on**
599 **multiple anthropometric traits identifies novel loci for body shape.** *Nat Commun*
600 2016, **7:13357.**
- 601 57. Richardson TG, Sanderson E, Elsworth B, Tilling K, Davey Smith G: **Use of genetic**
602 **variation to separate the effects of early and later life adiposity on disease risk:**
603 **mendelian randomisation study.** *BMJ* 2020, **369:m1203.**
- 604 58. Martin S, Cule M, Basty N, Tyrrell J, Beaumont RN, Wood AR, Frayling TM, Sorokin E,
605 Whitcher B, Liu Y *et al*: **Genetic Evidence for Different Adiposity Phenotypes and**
606 **Their Opposing Influences on Ectopic Fat and Risk of Cardiometabolic Disease.**
607 *Diabetes* 2021, **70(8):1843-1856.**
- 608 59. Leyden GM, Shapland CY, Davey Smith G, Sanderson E, Greenwood MP, Murphy D,
609 Richardson TG: **Harnessing tissue-specific genetic variation to dissect putative**
610 **causal pathways between body mass index and cardiometabolic phenotypes.** *Am J*
611 *Hum Genet* 2022, **109(2):240-252.**
- 612 60. Thorgeirsson TE, Gudbjartsson DF, Sulem P, Besenbacher S, Styrkarsdottir U,
613 Thorleifsson G, Walters GB, Consortium TAG, Oxford GSKC, consortium E *et al*: **A**
614 **common biological basis of obesity and nicotine addiction.** *Transl Psychiatry* 2013,
615 **3(10):e308.**
- 616 61. Wills AG, Hopfer C: **Phenotypic and genetic relationship between BMI and cigarette**
617 **smoking in a sample of UK adults.** *Addict Behav* 2019, **89:98-103.**
- 618 62. Gage SH, Sallis HM, Lassi G, Wootton RE, Mokrysz C, Davey Smith G, Munafo MR:
619 **Does smoking cause lower educational attainment and general cognitive ability?**
620 **Triangulation of causal evidence using multiple study designs.** *Psychol Med* 2022,
621 **52(8):1578-1586.**
- 622 63. Schellhas L, Haan E, Easey KE, Wootton RE, Sallis HM, Sharp GC, Munafo MR, Zuccolo
623 L: **Maternal and child genetic liability for smoking and caffeine consumption and**
624 **child mental health: an intergenerational genetic risk score analysis in the ALSPAC**
625 **cohort.** *Addiction* 2021, **116(11):3153-3166.**
- 626 64. Khouja JN, Wootton RE, Taylor AE, Davey Smith G, Munafo MR: **Association of**
627 **genetic liability to smoking initiation with e-cigarette use in young adults: A cohort**
628 **study.** *PLoS Med* 2021, **18(3):e1003555.**
- 629 65. Reed ZE, Wootton RE, Khouja JN, Richardson TG, Sanderson E, Davey Smith G,
630 Munafo MR: **Exploring pleiotropy in Mendelian randomisation analyses: What are**
631 **genetic variants associated with 'cigarette smoking initiation' really capturing?**
632 *Genet Epidemiol* 2024.
- 633 66. Gui L, He X, Tang L, Yao J, Pi J: **Obesity and head and neck cancer risk: a mendelian**
634 **randomization study.** *BMC Med Genomics* 2023, **16(1):200.**
- 635 67. Thomas SJ, Penfold CM, Waylen A, Ness AR: **The changing aetiology of head and**
636 **neck squamous cell cancer: A tale of three cancers?** *Clin Otolaryngol* 2018,
637 **43(4):999-1003.**
- 638 68. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, International
639 Agency for Research on Cancer Handbook Working G: **Body Fatness and Cancer--**
640 **Viewpoint of the IARC Working Group.** *N Engl J Med* 2016, **375(8):794-798.**

641 69. Mariosa D, Carreras-Torres R, Martin RM, Johansson M, Brennan P: **Commentary:**
642 **What can Mendelian randomization tell us about causes of cancer?** *Int J Epidemiol*
643 2019, **48**(3):816-821.
644

645

646 **Availability of data and materials**

647 All the GWAS datasets used in our study are publicly available. The GWAS summary statistics
648 for waist circumference by Shungin et al. are available via the IEU OpenGWAS platform (id:
649 ieu-a-61). The GWAS summary statistics for BMI and WHR by Pulit et al.[36] can be
650 downloaded from <https://zenodo.org/records/1251813>. The data sources for the other
651 adiposity-related measures have been specified in Table 1. The smoking behaviour traits
652 GWAS data were downloaded from
653 <https://data.bris.ac.uk/data/dataset/10i96zb8gm0j81yz0q6ztei23d> (for CSI) and
654 <https://doi.org/10.13020/przg-dp88> (for smoking initiation). The outcome datasets used in
655 our analyses have been uploaded to the IEU OpenGWAS project platform for reproducibility.
656 However, because the data was originally in build GRCh38, some multiallelic SNPs that could
657 not be aligned with GRCh37 Human Genome reference sequence were dropped when lifting
658 the data to build HG19/GRCh37 (which was required at the time of upload: April 2024). The
659 following IEU OpenGWAS id's were assigned to the European HEADSpAcE HNC GWAS
660 datasets including/excluding UK Biobank: ieu-b-5129/ieu-b-5123 for overall HNC, ieu-b-
661 5132/ieu-b-5126 for oral cavity cancer, ieu-b-5130/ieu-b-5124 for hypopharynx cancer, ieu-
662 b-5134/ieu-b-5128 for HPV positive oropharynx cancer, ieu-b-5133/ieu-b-5127 for HPV
663 negative oropharynx cancer, and ieu-b-5131/ieu-b-5125 for larynx cancer. The R code used
664 to run the MR analyses is available at http://github.com/fernandam93/adiposity_HNC_MR.
665

666 Acknowledgements

667 We thank Richard Wilkinson for proofreading several versions of the manuscript. We would
668 also like to thank Weili (Jason) Qiu, the IEU Data Manager, for his help debugging code and
669 uploading the HNC GWAS summary statistics to the IEU OpenGWAS platform.

670

671 Funding

672 FMB was supported by a Wellcome Trust PhD studentship in Molecular, Genetic and
673 Lifecourse Epidemiology (224982/Z/22/Z). RCR was supported by a Cancer Research UK
674 grant (C18281/A29019). MCB is supported by a University of Bristol Vice Chancellor's
675 Fellowship, the British Heart Foundation (AA/18/1/34219) and the UK Medical Research
676 Council (MC_UU_00032/05). GDS works within the MRC Integrative Epidemiology Unit at
677 the University of Bristol, which is supported by the Medical Research Council
678 (MC_UU_00011/1). CLR was supported by the Medical Research Council (MC_UU_00011/5)
679 and by a Cancer Research UK (C18281/A29019) programme grant (the Integrative Cancer
680 Epidemiology Programme). SV was funded by an EU Horizon 2020 grant (agreement number
681 825771). JK works in a unit that receives support from the University of Bristol and the UK
682 Medical Research Council (grant number: MC_UU_00032/7).

683

684 Competing interests

685 TGR works as a full-time employee for GlaxoSmithKline outside of this research. All other
686 authors declare no conflicts of interest.

687

688 IARC disclaimer

689 Where authors are identified as personnel of the International Agency for Research on
690 Cancer/World Health Organization, the authors alone are responsible for the views
691 expressed in this article and they do not necessarily represent the decisions, policy or views
692 of the International Agency for Research on Cancer/World Health Organization

Figures




Figure 1. Forest plot for the genetically predicted effects of body mass index on the risk of head and neck cancer and its subsites.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Figure 2. Forest plot for the genetically predicted effects of waist-to-hip ratio on the risk of head and neck cancer and its subsites.




Figure 3. Forest plot for the genetically predicted effects of waist circumference on the risk of head and neck cancer and its subsites.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Figure 4. Forest plot for the genetically predicted effects of BMI on the risk of HNC and its subsites, before (univariable-black) and after (multivariable-blue) accounting for comprehensive smoking index (CSI).




Figure 5. Forest plot for the genetically predicted effects of BMI on the risk of HNC and its subsites, before (univariable-black) and after (multivariable-blue) accounting for smoking initiation (SI).